32 results about "T-cell leukemia" patented technology

The invention discloses a gRNA (guide Ribonucleic Acid) target sequence capable of effectively knocking out CRISPR / Cas9 (Clustered regularly interspaced short palindromic repeats / CRISPR associated protein 9) of an HTLV-1 (Human T-cell Leukemia Virus type 1) virus genome and application of the gRNA target sequence. The gRNA target sequence comprises a first RNA forward sequence, a second RNA forward sequence, a first RNA reverse sequence and a second RNA reverse sequence, wherein the first RNA forward sequence and the first RNA reverse sequence are complementary with each other and comprise sequences shown as SEQ ID NO 01 and SEQ ID NO 02 respectively; the second RNA forward sequence and the second RNA reverse sequence are complementary with each other and comprise sequences shown as SEQ ID NO 03 and SEQ ID NO 04 respectively. The gRNA sequence disclosed by the invention can be used for effectively knocking out the HTLV-1 virus genome and can be used for effectively inhibiting proliferation of ATL (Adult T-cell Leukemia) cells and occurrence of tumors.

A composition for repressing transformation growth factor β contains theanine as an active substance. The composition is useful for preventing or treating chronic glomerulonephritis, renal interstitial fibrosis, hepatic fibrosis, hepatic cirrhosis, idiopathic interstitial pneumonia, keloid, hidebound disease, arterial sclerosis, myocardial infarction, cardiac fibrosis, restenosis, acute megakaryoblastic leukemia, adult T-cell leukemia, chronic fatigue syndrome or ordinary fatigue.

The invention provides a CD7 chimeric antigen receptor modified NK-92MI cell and an application thereof. Particularly, the invention provides an engineered NK cell that expresses a chimeric antigen receptor CAR, the antigen binding domain of which contains a nanoantibody VHH sequence targeting CD7. The NK cell can effectively kill tumor cells, especially T cell tumors, and has very good treatmenteffect on T cell leukemia (such as T-ALL).

The present invention provides an adult T cell leukemia model animal, which is a T cell function deficient animal to which a cell line infected with human T cell leukemia virus-1 is transplanted. This model animal allows the HTLV-1 infected cell line to proliferate over a long period of time, and enables not only the tumorigenesis process but also the mechanism of onset of ATL and immune response mechanism of the host against ATL to be precisely analyzed.

Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.

The invention belongs to the field of molecular biology and in particular relates to a primer combination and kit for detecting minimal residual diseases of T-cell leukemia by high-throughput sequencing. The primer combination is characterized by comprising a TCR (T Cell Receptor) 5'Oligo connector, a TCR 3'Oligo (dT) primer, a TCR C-region primer and upstream and downstream primers of a label; and the kit comprises the primer combination in claim 1 or 2. Full-length information of a TCR gene sequence is obtained from the upstream primer of the connector to a downstream primer of a C region.

A therapeutic agent comprising fucoxanthin or fucoxanthinol as an active component is disclosed. The therapeutic agent is effective and high clinical utility for medical treatment and prevention of virus-associated malignancy such as adult T-cell leukemia and Burkitt lymphoma.

Abacavir, a nucleoside analogue reverse transcriptase inhibitor, has been found to exhibit an anti-cancer activity on ATL cells in vitro without inhibiting DNA replication of normal cells. Abacavir or a pharmaceutically acceptable derivative thereof is useful as an active ingredient of a pharmaceutical composition for use in the prevention or the treatment of cancer, in particular a cancer whose DNA repair system is impaired such as breast cancer or adult T-cell leukemia.

The invention provides a preparation method and applications of a 4-phenoxy phenyl pyrazolo pyrimidine amide derivative. The compound has a structure represented by a formula (I), wherein X and Y aretwo linking groups, X is selected from benzyl, substituted benzyl, piperidyl and C1-6 straight-chain or branched-chain alkyl, Y is -(CH2)n-, n is any integer selected from 0-4, R is selected from hydroxyl, hydroxyamino and o-phenylenediamine, and the structure of the formula (I) comprises a racemate and a stereoisomer. The compound has a BTK / HDAC double-target inhibition effect and growth inhibition activity on T cell leukemia cells and mantle cell lymphoma cells, and is used for preparing antitumor drugs.

The invention discloses a method for detecting the minimal residual disease of T cell leukemia. The method comprises a multi-PCR primer, wherein the multi-PCR primer comprises an upstream primer and a downstream primer; the upstream primer is an upstream primer group formed by sequences of SEQ ID No:81 to SEQ ID No:112; the downstream primer comprises a nucleotide sequence of SEQ ID No:114. The detection method comprises the steps of (S1) extracting a human peripheral blood mononuclear cell to obtain a total RNA; (S2) carrying out multi-PCR reaction on the obtained RNA by adopting a one-step RT-PCR method to obtain a multi-PCR product; (S3) after multi-PCR reaction is completed, purifying the PCR product by magnetic beads and removing excessive primers; (S4) adding a basic group A to a 3' end of the purified multi-PCR product and obtaining a PCR product with a 3' cohesive end A; and (S5) connecting the PCR product with the 3' cohesive end A and a linker sequence to obtain a connection product containing a linker. According to the method for detecting the minimal residual disease of the T cell leukemia, the detection efficiency is improved and the method is suitable for popularization.

The invention belongs to the field of molecular biological detection, and in particular relates to an RNA linker and a single pair of primers for constructing a high-throughput sequencing library for a T cell receptor (TCR) of T cell leukemia minimal residual disease based on high-throughput sequencing, and a preparation method of the DNA library. The method comprises the following steps: acquiring 10mL of a human blood sample, and placing the human blood sample in an EDTA anticoagulative tube; separating peripheral blood mononuclear cells (PBMC) by adopting lymphocyte separating liquid Ficoll-1077; extracting total RNA of PBMC by adopting a Trizol method, wherein the used reagent is RNAzol RT; carrying out inverse transcription on RNA to form cDNA, and meanwhile, adding a linker at the 5' terminal of cDNA; carrying out PCR1; carrying out PCR2 and purification; and carrying out high-throughput sequencing, and thus the full-length information of a TCR gene sequence is obtained from an upstream primer of the linker and a downstream primer of the C region.

The invention relates to a specific targeted polypeptide for adult T-cell leukemia and application of the specific targeted polypeptide. The specific targeted polypeptide for treating the adult T-cell leukemia is screened by taking a key viral protein HBZ encoded by infective pathogen human T-cell leukemia virus type 1 of the adult T-cell leukemia (ATL) as a target and can be used for preparing a targeted drug for treating the adult T-cell leukemia. Compared with traditional treatment measures of anti-tumor drugs, the targeted drug and the targeted treatment measure based on the specific targeted polypeptide have the advantages that the toxic and side effects of cells are relatively low, and a brand-new thought and strategy are provided for researching drugs resisting HTLV-1 and ATL in future.

Provided are engineered primary blood and monocyte-derived dendritic cells, wherein the dendritic cell expresses a functional Tax protein from a T cell leukemia virus, and methods of making and using the same.

The invention relates to a diagnostic kit for ALT (adult T-cell leukemia) and a drug for treating ALT. It is discovered for the first time that detection of the expression level of ANRIL in ATL cellscan become one of diagnostic indexes of ALT and proliferation of the ATL cells can be effectively inhibited and apoptosis of the ATL cells can be effectively promoted through specific interference / knockdown of expression level of ANRIL, and accordingly, the kit for diagnosing ALT and the drug for treating ALT are developed, and a new approach and strategy are provided for diagnosis and treatment of ALT.

The present invention provides an adult T cell leukemia model animal, which is a T cell function deficient animal to which a cell line infected with human T cell leukemia virus-1 is transplanted. This model animal allows the HTLV-1 infected cell line to proliferate over a long period of time, and enables not only the tumorigenesis process but also the mechanism of onset of ATL and immune response mechanism of the host against ATL to be precisely analyzed.

The invention provides a composition capable of enhancing organism immunity and an application of the composition to resisting adult T-cell leukemia or nasopharyngeal carcinoma. The composition contains a dendritic cell vaccine and a novel immunity checkpoint inhibitor NKG2A antagonist, and is used for treating the adult T-cell leukemia and the nasopharyngeal carcinoma. The source of dendritic cells in the composition is firstly dendritic cells extracted from patients or animals, when the extracted dendritic cells are mature after being cultured in vitro and induction, specific cancer antigensare loaded to the dendritic cells which are extracted from the patients or the animals, corresponding antigens are formed on the surfaces of the dendritic cells, then the dendritic cells having the corresponding antigens on the surfaces and an NKG2A antagonist are transported back to patient bodies together to stimulate natural immunity and induce natural killer cells and T lymphocyte to producean acquired immunity reaction, the quantity of in vivo viruses is reduced, and cytotoxic T cells are activated to kill and destroy cancer cells to treat the adult T-cell leukemia and the nasopharyngeal carcinoma.

Abacavir, a nucleoside analog reverse transcriptase inhibitor, has been found to exhibit an anti-cancer activity on ATL cells in vitro without inhibiting DNA replication of normal cells. Abacavir or a pharmaceutically acceptable derivative thereof is useful as an active ingredient of a pharmaceutical composition for use in the prevention or the treatment of cancer, in particular a cancer whose DNA repair system is impaired such as breast cancer or adult T-cell leukemia.

An adult T-cell leukemia-lymphoma (ATL) detection method is provided which involves determining the presence or absence in a target biological sample of DNA methylation of at least one gene selected from the group consisting of SERPINB6, NELL2, THEMIS, ZSCAN18, LAIR1, CD7, RNF130, ZIK1, LYPD3, TMEM45B, POMC, FHIT, MDS2, HOOK1, SORCS3, C2orf40, ZNF662, SPG20, ZNF717, LZTFL1, KLHL34 and BCL9, wherein DNA methylation of at least one of the aforementioned genes indicates that the subject has developed or is at risk of developing ATL. By this means, a new detection method of adult T cell leukemia-lymphoma (ATL) is provided.

An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof,wherein R1 is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R2 is an acyl group, a thioacyl group, CONR7R8, or CSNR7R8 (R7 and R8 being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R1 and R2 together may form a ring, X1 and X2 may be the same or different and are each —CR3R4—, —SiR3R4— or oxygen, and R3 and R4 may be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.

Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.

The invention discloses a method for detecting anti-CD19 chimeric antigen receptor T cell effects of inhibiting leukemia cells. The method comprises 1, mixing anti-CD19 chimeric antigen receptor T cells and leukemia cells according to a certain ratio, and transplanting the mixed cells into an immunodeficient mouse model, wherein the anti-CD19 chimeric antigen receptor T cell has an accession number of CCTCC NO: C201503, 2, carrying out immunodeficient mouse model peripheral blood cell dyeing, and 3, detecting the dyed peripheral blood cells by a flow cytometer. Human leukemia cells and leukemia cell inhibition cells are transplanted into an immunodeficient mouse model together so that effects of inhibiting different human leukemia cells can be really shown and high effectiveness and accuracy of the inhibition effect detection method are guaranteed.

The present invention relates to compositions and methods that may be used to diagnose and treat cancer, particularly T-cell leukemia. According to one preferred embodiment of the present invention, methods are provided for determining whether reducing or blocking NOTCH-1 activation will be effective to treat, prevent, or ameliorate the effects of a cancer in a patient, including T-cell leukemia, myeloleukemia, neuroblastoma, breast cancer, and ovarian cancer. The methods generally include determining if the patient harbors one or more mutations in a PTEN coding region. In particular, the methods may be used to determine whether reducing or blocking NOTCH-1 activation, with one or more γ-secretase inhibitors, will be effective to treat, prevent, or ameliorate the effects of a cancer in a patient.

Protein biomarkers that may advantageously be utilized in aiding in, or making, a diagnosis of HTLV-I-associated myelopathy (HAM), adult T-cell leukemia (ATL) or a negative diagnosis are described. Accordingly, in one aspect of the invention, methods for aiding in, or otherwise making, a diagnosis of ATL, HAM or a negative diagnosis are provided. Methods of detecting the protein biomarkers, kits that may be utilized to detect the biomarkers, as well as isolated protein biomarkers are also provided.

Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.

The invention belongs to the field of gene engineering, and particularly relates to a construction method of a T-cell tumor phage antibody library. The method comprises the steps of amplifying heavy chains and heavy chain variable genes of a full set of human antibodies from peripheral blood mononuclear cells of a healthy crowd and T cell leukemia / lymphoma patients, crossing and overlapping to form an antibody SCFV (Single Chain Fragment Variable) gene segment, then inserting into a phage vector pCanTab5F, and constructing the T-cell tumor phage antibody library. The invention relates to a monoclonal antibody screened through the method. The special phage antibody library is constructed aiming at T-cell tumors, and has higher sensibility and specificity than an existing commercialized antibody library. The constructed T cell leukemia / lymphoma phage antibody library has the capacity being 2.70*10<8> and meets the standards of a large-capacity antibody library. The antibody library is mainly used for high-throughput screening anti-CDR3 high-affinity humanized antibodies targeting T cell leukemia / lymphoma.

An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof,wherein R1 is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R2 is an acyl group, a thioacyl group, CONR7R8, or CSNR7R8 (R7 and R8 being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R1 and R2 together may form a ring, X1 and X2 may be the same or different and are each —CR3R4—, —SiR3R4— or oxygen, and R3 and R4 may be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.